Originally posted by dmk112
View Post
Just goes to show 'ya, good data doesn't necessarily mean approval. They were denied because of side effects and long term safety data. (Disclosure: one of the ingredients is topiramate, which I am extremely allergic to. Yuk) But is this an excuse because of FDA "bias?" (see below).
For further amusement, check this out: http://www.thestreet.com/story/10806...ory-panel.html
Vivus doesn't have much of anything else in the pipeline except a phase 3 clinical trial of an oral ED drug, with results expected in late 2010. I don't put too much faith in a competitor for the little blue pill and the other one either. Stockcharts shows how much Vivus dropped after the announcement. Ouch. I wouldn't touch it here.
The announcement obviously has an effect on Arena Pharm also, since they have submitted their obesity drug lorcaserin phase 3 clinical data for approval, on or before October 22, 2010. It doesn't look good for this one either unless the FDA changes their bias for exercise instead of drugs. http://blogs.wsj.com/health/2010/07/.../?mod=yahoo_hs
But, Arena's works as a serotonin inhibitor, like many other drugs. Maybe there won't be a problem.
A little too much risk for my tolerance, altho buying it if it pulls back Mon+ on the news, and selling on a run up before the Oct. announcement would be a possibility. A really low-ball bid I think, around $3-3.50, or raise it slightly if it starts to look better on volume. I wouldn't bet the farm. Good luck dmk. And thanks for bringing these here.


Leave a comment: